Clinical efficacy of the gonadotropin‐releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle‐stimulating hormone

Abstract

The results of the present study support ganirelix as a safe, short, convenient and effective treatment for patients undergoing COH for IVF in Korean women.

Cryopreservation of supernumerary high quality embryos predicts favorable outcomes for patients undergoing repeated cycles of in vitro fertilization

“…A recent meta-analysis (17) combining more than 13 prospective randomized controlled trials (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) found a significant reduction in ongoing PRs/live birth rates in patients treated with GnRH antagonist compared to those of patients treated with traditional GnRH agonist (OR 0.82, P¼.03). The effect remained significant even after controlling for potential confounders.…”

Appropriate methods to monitor controlled ovarian hyperstimulation?

“…Especially, the investigators dealing with IVF had reported the hopeful results in the patients defined as poor responders (2). The results of many trials had documented the significant positive effect of GnRH antagonist in poor responder patients compared with agonists, and the similar pregnancy rates in the two group of patients were also suggested (3,4). Moreover, GnRH antagonists were found to be associated with simpler stimulation protocols, lower gonadotropin requirements, and reduced patient costs.…”

“…These observations were explained by either the possible deleterious effect of GnRH antagonists, which have a known inhibitory effect on the cell cycle by decreasing the synthesis of growth factors, or by the beneficial effect of GnRH agonists. For examole, Fujii et al (3) noted that GnRH-agonist administration throughout the luteal phase and early pregnancy positively influenced implantation and pregnancy outcome.…”